Interleukin Patents (Class 424/85.2)
  • Patent number: 11116752
    Abstract: Disclosed is a pharmaceutical composition containing a bicyclo-substituted pyrazolone azo derivative or a salt thereof and a preparation method thereof. In particular, the pharmaceutical composition disclosed in the present invention contains (Z)-5-(2-hydroxyl-3-(2-(3-methyl-5-oxo-1-(5,6,7,8-tetrahydronaphthalene-2-yl)-1H-pyrazol-4(5H)-ylidene)hydrazino)phenyl)furan-2-carboxylic acid or a pharmaceutically acceptable salt thereof, and at least one filler optionally selected from cellulose, microcrystalline cellulose, lactose and starch. The composition has a good stability, dissolution rate and bioavailability, and the preparation process is simple, economical and quick.
    Type: Grant
    Filed: January 16, 2017
    Date of Patent: September 14, 2021
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Yun Lu, Xinhua Zhang, Daimei Zhang
  • Patent number: 11116771
    Abstract: Imipridones has been found to selectively modulate Class A G protein-coupled receptors (GPCRs), such as the D2-like subfamily of dopamine receptors, and to be useful for the treatment of conditions and disorders in need of such modulation, such as cancers, psychiatric disorders, and bacterial infections. In addition, methods of identifying whether a subject having these condition, is likely to be responsive to a treatment regimen, such as administration of an imipridone, are provided. Furthermore, methods of assessing the effectiveness of a treatment regimen, such as administration of an imipridone, monitoring, or providing a prognosis for a subject with these condition are also provided.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: September 14, 2021
    Assignee: Oncoceutics, Inc.
    Inventors: Joshua E. Allen, Martin Stogniew, Varun Vijay Prabhu
  • Patent number: 11110157
    Abstract: The present invention relates to a vaccine/agonist combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one OX40 agonist. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/agonist combination. Additionally the present invention relates to medical use of such a vaccine/agonist combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/agonist combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with an OX40 agonist.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: September 7, 2021
    Assignee: CureVac AG
    Inventors: Mariola Fotin-Mleczek, Karl-Josef Kallen, Jan C. Schmollinger
  • Patent number: 11098099
    Abstract: The present invention generally relates to fusion proteins of immunoglobulins and interleukin-2 (IL-2). More particularly, the invention concerns fusion proteins of immunoglobulins and mutant IL-2 that exhibit improved properties for use as therapeutic agents, e.g. in the treatment of autoimmune diseases and immune-mediated inflammatory diseases. In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: August 24, 2021
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Christian Klein, Pablo Umana, Ekkehard Moessner, Ralf Hosse, Laurence Bernard Peterson, Linda Wicker
  • Patent number: 11098101
    Abstract: This disclosure describes engineered compounds that engage NK cells and methods of using the compounds. Generally, the compound includes an NK engaging domain, a targeting domain that selectively binds to a target cell, and an NK activating domain operably linking the NK engaging domain and the targeting domain.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: August 24, 2021
    Assignee: Regents of the University of Minnesota
    Inventors: Daniel Attilio Vallera, Jeffrey S. Miller
  • Patent number: 11098100
    Abstract: This disclosure describes engineered compounds that engage NK cells and methods of using the compounds. Generally, the compound includes an NK engaging domain, a targeting domain that selectively binds to a target cell, and an NK activating domain operably linking the NK engaging domain and the targeting domain.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: August 24, 2021
    Assignee: Regents of the University of Minnesota
    Inventors: Daniel Attilio Vallera, Jeffrey S. Miller
  • Patent number: 11078535
    Abstract: Compositions and methods are provided for the early detection of neuroinflammation in a patient in a presymptomatic stage of a neurodegenerative disease. The method comprises identifying patients with elevated expression levels of a micro RNA selected from the group consisting of miR142-3p, miR142-5p, miR181a, miR181b, miR219-3p and miR219-5p. The identified patients can then be treated with a therapeutic pharmaceutical composition comprising antimiR oligonucleotides.
    Type: Grant
    Filed: July 7, 2018
    Date of Patent: August 3, 2021
    Assignee: The Trustees of Indiana University
    Inventors: Salil Sharma, Hui-Chen Lu
  • Patent number: 11065330
    Abstract: The invention relates to a pharmaceutical composition for modulation of T cell and B cell responses by antigen- or allergen-specific immunotherapy in combination with peripheral tolerance-inducing phagocytosis, made of one or more preparations and comprising one or more matrices suitable for locally restricted sustained release of a physiologically effective dose of at least one antigen or allergen, liposomes tailored for effective phagocytosis, one or more immune modulators of phagocytosis, and one or more immune modulators suitable for enhancing the suppressive function of regulatory T cells at the site of antigen or allergen presentation.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: July 20, 2021
    Assignee: PLS-Design GmbH
    Inventors: Reinhard Bredehorst, Thomas Grunwald, Carsten Schmidt-Weber
  • Patent number: 11058664
    Abstract: A method of treating a pediatric cancerous solid tumor in a mammalian subject is disclosed that comprises intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor. Another contemplated method comprises the steps of intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor and systemically administering a tumor-inhibiting effective amount of a systemic anti-cancer medication that provides synergistic cytotoxicity with the halogenated xanthene. The two administrations can occur concurrently, or one prior to the other.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: July 13, 2021
    Assignees: Provectus Pharmatech, Inc., UTI Limited Partnership
    Inventors: Jamie Singer, Eric A. Wachter, Satbir Thakur, Lucy Swift, Chunfen Zhang, Mohit Jain, Aru Narendran
  • Patent number: 11045418
    Abstract: The present invention relates to lipid particles comprising at least one cationic lipid, at least one water-soluble therapeutically effective compound and RNA. Further, the present invention relates to a pharmaceutical composition comprising such particles. Said pharmaceutical composition is useful for inducing an immune response. It is also useful in a prophylactic and/or therapeutic treatment of a disease involving an antigen. Furthermore, the present invention relates to a method for producing the particles.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: June 29, 2021
    Assignees: BioNTech RNA Pharmaceuticals GmbH, Tron-Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz
    Inventors: Hossam Hefesha, Ugur Sahin, Heinrich Haas, Sebastian Kreiter, Yves Hüsemann, Mustafa Diken, Kerstin Walzer
  • Patent number: 11041008
    Abstract: The present invention provides method for promoting the maturation and export of T cells from thymic tissue by contacting the thymic tissue with supraphysiological levels of interleukin (IL)-15. The present invention also provides methods for preventing, alleviating, reducing, and/or inhibiting lymphopenia or peripheral depletion of lymphocytes in a patient in need thereof by administering to the patient IL-15.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: June 22, 2021
    Assignee: The Government of the United States of America as Represented by The Secretary of the Department of Health and Human Services
    Inventors: Cristina Bergamaschi, Barbara K. Felber, George N. Pavlakis, Antonio Valentin
  • Patent number: 11020467
    Abstract: Methods and compositions for generating enhanced immune responses using adenovirus vectors that allow for multiple vaccinations in combination with an IL-15 superagonist complex in subjects in need thereof are provided.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: June 1, 2021
    Assignee: Etubics Corporation
    Inventors: Frank R. Jones, Adrian Rice, Elizabeth Gabitzsch, Yvette Latchman, Joseph Balint
  • Patent number: 11008404
    Abstract: The invention relates to antibodies to MASP-2 and functional equivalents thereof. In particular, the invention relates to MASP-2 antibodies capable of inhibiting the function of MASP-2. The invention furthermore discloses MASP-2 epitopes, wherein antibodies recognising said epitopes are in particularly useful for inhibiting MASP-2 activity. The invention also relates to methods of producing said antibodies, methods of inhibiting MASP-2 activity as well as to pharmaceutical compositions comprising the MASP-2 antibodies.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: May 18, 2021
    Assignee: Helion Biotech ApS
    Inventors: Flemming Larsen, Ulla Wahlers
  • Patent number: 11007222
    Abstract: The present invention provides an isolated cell composition, which in some embodiments is suitable for adoptive immunotherapy, as well as methods of manufacturing the cell compositions and methods of treatment with the cell compositions. The composition comprises, in a pharmaceutically acceptable carrier, at least about 106 CD8+ T cells specific for target peptide antigen(s), which comprises T memory stem (TSCM) cells. In various embodiments, the composition is from about 1% to about 100% T memory stem cells, providing for a robust and durable adoptive therapy, as well as providing for T cell engineering advances.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: May 18, 2021
    Assignee: NEXIMMUNE, INC.
    Inventors: Mathias Oelke, Kristi Jones, Sojung Kim, Lauren Suarez, Ken Carter, Scott Carmer, Dan Bednarik, Vineetha Edavana, Emily Lu
  • Patent number: 11008405
    Abstract: The invention relates to antibodies to MASP-2 and functional equivalents thereof. In particular, the invention relates to MASP-2 antibodies capable of inhibiting the function of MASP-2. The invention furthermore discloses MASP-2 epitopes, wherein antibodies recognising said epitopes are in particularly useful for inhibiting MASP-2 activity. The invention also relates to methods of producing said antibodies, methods of inhibiting MASP-2 activity as well as to pharmaceutical compositions comprising the MASP-2 antibodies.
    Type: Grant
    Filed: January 7, 2020
    Date of Patent: May 18, 2021
    Assignee: Helion Biotech ApS
    Inventors: Flemming Larsen, Ulla Wahlers
  • Patent number: 10994027
    Abstract: Provided is a novel vector for immunostimulation and methods of using same in immunotherapy, in particular cancer immunotherapy. The novel vector comprises nucleic acid sequences encoding 4-1BB ligand (4-1BBL, CD137 ligand), single chain IL-12 (sc IL-12) and IL-2, wherein the vector provides for an increased expression of 4-1BBL as compared to the expression levels of sc IL-12 and IL-2. Specifically, the nucleic acid sequences encoding 4-1BBL, sc IL-12 and IL-2 are organized in the vector in 5? to 3? orientation in a sequential order 1, 2, 3, with the proviso that the gene encoding sc IL-12 is not at position 1. Embodiments of the present disclosure include virus particles comprising the novel vector as well as cancer or immune cells transduced or transfected with the novel vector.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: May 4, 2021
    Assignee: Provecs Medical GmbH
    Inventors: Frank Schnieders, Andrea Miegel, Carolin Biermann-Fleischhauer
  • Patent number: 10987371
    Abstract: A method of reducing the risk of filovirus hemorrhagic fever or a symptom thereof in a mammal host exposed to a filovirus (e.g., Ebola or Zika virus), comprising administering an effective amount of quercetin-3 ?-O-D-glucoside (Q3G) or an analogue thereof, or a composition comprising Q3G or analogue thereof and a pharmaceutically acceptable carrier, to said host prior to said exposure.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: April 27, 2021
    Inventors: Michel Chrétien, Majambu Mbikay, Xiangguo Qiu
  • Patent number: 10987403
    Abstract: Disclosed herein are compositions including cyclodextrin and Nle3-A(1-7) [Asp-Arg-Me-Tyr-Ile-His-Pro (SEQ ID NO: 1)] and their use in treating various disorders.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: April 27, 2021
    Assignee: University of Southern California
    Inventors: Kevin J. Gaffney, Stan G. Louie, Kathleen E. Rodgers
  • Patent number: 10981903
    Abstract: The present invention provides novel compounds according to Formula (I): where Ring A, Ring B, X, L1, L2, RA, RC, RD, RE, m, n, and p are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of human diseases associated with kinase activity, for example, proliferative diseases, neurodegenerative diseases, metabolic disorders, inflammatory diseases, and cardiovascular diseases.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: April 20, 2021
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael S. Gray, Tinghu Zhang
  • Patent number: 10967070
    Abstract: Provided herein are cell penetrating conjugates. The conjugates include a non-cell penetrating protein attached to a phosphorothioate nucleic acid or phosphorothioate polymer backbone, wherein the phosphorothioate nucleic acid or phosphorothioate polymer backbone enhances intracellular delivery of the non-cell penetrating protein. Also provided are compositions and kits comprising the cojugates.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: April 6, 2021
    Assignee: CITY OF HOPE
    Inventors: Andreas Herrmann, Hua Yu, Piotr Marek Swiderski, John Ernest Shively, Lin Li
  • Patent number: 10966927
    Abstract: The present disclosure is broadly concerned with petrolatum-based compositions as a suspension matrix for the active ingredients. The disclosure is also concerned with processes for forming stable emulsions of active ingredients in petrolatum.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: April 6, 2021
    Assignee: GLOBAL HEALTH SOLUTIONS LLC
    Inventor: Bradley Burnam
  • Patent number: 10967060
    Abstract: The present disclosure provides combinations of immunologic inhibitors for the treatment of cancer. In some embodiments, the methods involve the use of a combination of at least two of the following: an inhibitor of indoleamine-2,3-dioxygenase (IDO), an inhibitor of the PD-L1/PD-1 pathway, an inhibitor of CTLA-4, an inhibitor of CD25, or IL-7.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: April 6, 2021
    Assignee: The University of Chicago
    Inventors: Thomas F. Gajewski, Stefani Spranger, Michael Leung
  • Patent number: 10954492
    Abstract: Described are improved processes for production and purification of nucleic acid-containing compositions, such as non-naturally occurring viruses, for example, recombinant polioviruses that can be employed as oncolytic agents. Some of the described improved processes relate to improved processes for producing viral DNA template. Also described are improved processes for chromatography purification of nucleic acid-containing compositions, in which the nucleic acid is quantified in chromatography fractions using a rapid detection method of the one or more nucleic acid sequences of the nucleic acid-containing composition, such as detection by real time RT-qPCR. In addition, improved processes for production and purification of oncolytic poliovirus, such as PVS-RIPO, are described. Compositions generated using these methods are also provided.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: March 23, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Trevor Lane Broadt, Samir Hussein Shaban, Yueqing Xie, Jianwei Sean Zhu, George Mitra
  • Patent number: 10946022
    Abstract: Imipridones selectively modulate Class A G protein-coupled receptors (GPCRs), such as the D2-like subfamily of dopamine receptors, and are useful for treating conditions and disorders in need of such modulation, such as cancers. Specifically, the cancer is a midline glioma, a cancer having a histone H3 mutation, or both. In addition, methods of identifying whether a subject having these conditions, is likely to be responsive to a treatment regimen, such as imipridone administration, are provided. Furthermore, methods of assessing the effectiveness of a treatment regimen, such as imipridone administration, monitoring, or providing a prognosis for a subject with these condition are also provided.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: March 16, 2021
    Assignee: ONCOCEUTICS, INC.
    Inventors: Joshua E. Allen, Martin Stogniew, Varun Vijay Prabhu
  • Patent number: 10940200
    Abstract: The present invention provides methods of modulating an immunological disorder or an immune response. The methods include administering to a subject or a cell an effective amount of an autoimmune antigen and an anti-inflammatory cytokine included in an aluminum-based carrier. Compositions including an autoimmune antigen and an anti-inflammatory cytokine included in an aluminum-based carrier are also provided.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: March 9, 2021
    Assignee: East Carolina University
    Inventor: Mark D. Mannie
  • Patent number: 10912798
    Abstract: A method is provided, inter alia, for treating a subject suffering from an infectious or neoplastic disease with immunotherapy. The method includes determining the critical concentration of immune cells required to treat or eradicate an infectious or neoplastic disease in the subject using an in vitro assay of the present invention; and administering to the subject the critical concentration of immune cells determined in the assay.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: February 9, 2021
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Samuel C. Silverstein, John D. Loike, Sadna Budhu, Peter Lee
  • Patent number: 10906952
    Abstract: The present invention relates to fusion proteins comprising a binding protein and an IL-15 polypeptide as well as uses thereof, pharmaceutical compositions comprising such fusion proteins and a method for producing such fusion proteins.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: February 2, 2021
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, EBERHARD KARLS UNIVERSITÄT TÜBINGEN
    Inventors: Jung Gundram, Helmut Salih, Cornelia Lindner, Berit Lochmann
  • Patent number: 10888621
    Abstract: Provided are an injectable tissue adhesive hydrogel including gamma-cyclodextrin (?-CD). When such an injectable tissue adhesive hydrogel including the ?-CD is used as a skin glue, based on a fact that the ?-CD has a bigger hydrophobic cavity than that of ?- and ?-CDs, the injectable tissue adhesive hydrogel including the ?-CD has stronger interactions than host-guest interactions. In addition, hydrogen bonding in the injectable tissue adhesive hydrogel including the ?-CD can improve both cohesiveness and adhesiveness of gelatin. The injectable tissue adhesive hydrogel including the ?-CD having excellent cell viability is used for adhesion of a skin incision, to thereby effectively promote tissue regeneration.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: January 12, 2021
    Assignees: AJOU UNIVERSITY INDUSTRY—ACADEMIC COOPERATION FOUNDATION, INCHEON UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION
    Inventors: Ki Dong Park, Kyung Min Park, Yun Ki Lee, Thi Thai Thanh Hoang, Thi Phuong Le
  • Patent number: 10889653
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: January 12, 2021
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • Patent number: 10865230
    Abstract: The invention features soluble fusion protein complexes comprising at least two soluble fusion proteins. For example, the first fusion protein is an anti-CD3 antibody covalently linked to an interleukin-15 (IL-15) polypeptide or functional fragment thereof. The second fusion protein comprises a binding domain that recognizes disease antigens, wherein this domain is covalently linked to a soluble interleukin-15 receptor alpha (IL-15R?) polypeptide or a functional fragment thereof. One or both of the first and second fusion proteins further includes an immunoglobulin Fc domain or a functional fragment thereof, and the IL-15 domain of first fusion protein binds to the soluble IL-15R? domain of the second fusion protein to form a soluble fusion protein complex. The invention further provides methods for making and using the complexes of the invention.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: December 15, 2020
    Assignee: ALTOR BIOSCIENCE, LLC
    Inventors: Bai Liu, Peter Rhode, Hing C. Wong
  • Patent number: 10865226
    Abstract: Peptides exhibiting melanogenesis promoting activity are described. The peptides increase the activity and expression of tyrosinase and the expression of factors involved in melanogenesis, thereby exhibiting an outstanding effect on melanogenesis. The peptides can be used for the prevention, alleviation, and treatment of hypomelanosis. The outstanding activity and stability stated above allow the peptides to be very favorably applied to medicines, quasi-medicines, and cosmetics.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: December 15, 2020
    Assignee: CAREGEN CO., LTD.
    Inventors: Yong Ji Chung, Eun Mi Kim, Eung-Ji Lee
  • Patent number: 10849963
    Abstract: The present invention relates to a medicament for use in a method of inducing a cellular cytotoxic immune response, the method comprising the steps of: i) administering to a patient a delivery system comprising (a) a molecule binding to a receptor on the surface of a dendritic cell, (b) an antigen-comprising protein bound to molecule of (a) and (c) a first adjuvant, wherein upon binding of the molecule of (a) to the receptor, the protein of (b) is internalized and processed in the dendritic cell and the antigen comprised in the protein is presented on the surface of the dendritic cell, thereby activating a T cell in the patient; and ii) administering to the patient a re-activator selected from the group consisting of (d) complexed interleukin 2 (IL-2cx), (e) a peptide-loaded major histocompatibility complex class I (MHC-I) presenting cell and a second adjuvant, and (f) a combination of (d) and (e), wherein the peptide is derived from the antigen-comprising protein as defined in step i), thereby reactivating t
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: December 1, 2020
    Assignee: Bundesrepublik Deutschland letztvertreten durch das Robl Koch-Institut vertreten durch seinen Präsidenten
    Inventor: Richard Kroczek
  • Patent number: 10836995
    Abstract: The present invention is related to a medium additive composition comprising peroxidasin for serum-free cell culture, and a method of performing serum-free culture of cells by using the same.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: November 17, 2020
    Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Young Ae Joe, Hyun-Kyung Kim
  • Patent number: 10829535
    Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: November 10, 2020
    Assignee: Amgen Inc.
    Inventors: Marc A. Gavin, Gunasekaran Kannan, Li Li, Joshua T. Pearson, Margaret Karow
  • Patent number: 10818377
    Abstract: Described herein are polypeptides capable of self-assembling to form homo-oligomers, and methods for designing such polypeptides.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: October 27, 2020
    Assignee: University of Washington
    Inventors: David Baker, Jorge Fallas, George Ueda, William H. Sheffler, Vanessa Nguyen
  • Patent number: 10808016
    Abstract: The invention relates to peptides such as HCPYCSLQPLALEGSLQKRG and their use in the treatment of type 1 diabetes and the generation of cytolytic CD4+ T cell.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: October 20, 2020
    Assignee: IMCYSE SA
    Inventors: Luc Vander Elst, Vincent Carlier, Jean-Marie Saint-Remy
  • Patent number: 10799473
    Abstract: Accelerated senescence has been shown to occur as a primary response to cellular stresses including DNA damaging agents (e.g., ionizing radiation) and is widely believed to be caused by continuous proliferative signaling in the presence of cell cycle arrest. The present disclosure provides a method of reducing cellular senescence in non-cancerous cells following exposure to ionizing radiation. The method comprises administering to a subject before, after, or concurrently with exposure to ionizing radiation an effective amount of a compound that inhibits activation of an insulin-like growth factor receptor (IGF-1R) or a compound that inhibits a protein involved in an IGF-1R induced signaling cascade.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: October 13, 2020
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Regina M Day, Ronald-Allan M Panganiban
  • Patent number: 10793632
    Abstract: The present invention is directed to bispecific, heterodimeric immunomodulatory antibodies.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: October 6, 2020
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon
  • Patent number: 10793875
    Abstract: Cancer immunotherapy is enhanced by co-expression of cancer associated or tumor-specific (neo)epitopes with co-stimulatory molecules and/or other immune activators. Where desired, treatment may be enhanced by administration of a immune checkpoint inhibitor.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: October 6, 2020
    Assignee: Nant Holdings IP, LLC
    Inventors: Patrick Soon-Shiong, Shahrooz Rabizadeh, Kayvan Niazi
  • Patent number: 10786551
    Abstract: The present invention relates to use of interleukin-22 (IL-22) for treating fatty liver disease by decreasing the levels of transaminases. The use of IL-22 in decreasing the levels of transaminases is also provided.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: September 29, 2020
    Assignee: Generon (Shanghai) Corporation Ltd.
    Inventors: Yu Liang Huang, Zhi Hua Huang, Qi Sun
  • Patent number: 10780128
    Abstract: We describe a particle secreted by a mesenchymal stem cell and comprising at least one biological property of a mesenchymal stem cell. The biological property may comprise a biological activity of a mesenchymal stem cell conditioned medium (MSC-CM) such as cardioprotection or reduction of infarct size. The particle may comprise a vesicle or an exosome.
    Type: Grant
    Filed: July 28, 2014
    Date of Patent: September 22, 2020
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR)
    Inventor: Sai Kiang Lim
  • Patent number: 10781242
    Abstract: The present invention relates to interleukin-2 fusion proteins. More specifically, the invention provides, in part, fusion proteins that include a interleukin-2 protein moiety joined to a Bcl-2 family member protein moiety.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: September 22, 2020
    Assignee: Medicenna Therapeutics Inc.
    Inventor: Fahar Merchant
  • Patent number: 10774149
    Abstract: The invention provides fusion proteins comprising antigens of infectious disease agents and cancer cells linked to multiple-trimer forms of TNF SuperFamily (TNFSF) ligands. The TNFSFs serve as vaccine adjuvants for increasing the immune response to the antigens. In particular, a fusion polypeptide strand that self-assembles inside cells into a multiple-trimer form of CD40 ligand (CD40L, TNFSF5) is provided. Other similar fusion proteins are also disclosed. The fusion proteins can be delivered to a host as isolated proteins, as nucleic acids used directly in DNA vaccination or carried and expressed by a viral vector such as adenovirus. In addition to use as a vaccine to prevent or ameliorate disease caused by an infectious agent, compositions of the invention may be used for the treatment of ongoing infection or for cancer immunotherapy.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: September 15, 2020
    Assignee: UNIVERSITY OF MIAMI
    Inventors: Geoffrey W. Stone, Richard S. Kornbluth
  • Patent number: 10772967
    Abstract: The teachings provide methods of delivering active agents that are conjugated with delivery systems that increase the half-life, and reduce the immunogenicity, of the active agents. Delivery systems and methods of making and using the delivery systems are also provided. The delivery systems have (i) a ligand that is selective for an endogeneous plasma protein in the serum of a subject; and, (ii) a linker configured for operatively attaching the ligand covalently to an active agent to increase the half-life of the active agent in the serum.
    Type: Grant
    Filed: February 7, 2020
    Date of Patent: September 15, 2020
    Inventor: Mamoun M Alhamadsheh
  • Patent number: 10765135
    Abstract: The present invention provides novel compositions and methods for producing protein-polysaccharide conjugates in aqueous solutions. Also provided are methods for limiting the Maillard reaction to the very initial stage, the formation of the Schiff base. Provided are methods to obtain a simple product of Schiff base with white color, and compositions obtained using the methods of the present invention.
    Type: Grant
    Filed: March 19, 2009
    Date of Patent: September 8, 2020
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: John A. Lucey, Dani Zhu, Srinivasan Damodaran
  • Patent number: 10744160
    Abstract: Aspects of the invention relate to a novel mesenchymal stem cell line (hb-MSC), a culture medium conditioned by the hb-MSC line, and various hb-MSC compositions. The hb-MSC composition may include a plurality of hb-MSCs, an hb-MSC conditioned medium, or a combination thereof. The hb-MSC composition may also include an appropriate carrier. Also described are methods of use for the hb-MSC cells, the conditioned medium and compositions thereof.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: August 18, 2020
    Assignee: T-Helper Cell Technologies, LLC
    Inventors: Anatoliy Sokolov, Antonina Ivanovna Kolesnikova, Andrei Igorevich Dovgii
  • Patent number: 10738096
    Abstract: Disclosed herein are IL-4 cytokine compositions with enhanced biological activity having increased selectivity for IL-4 cytokine receptors, and methods for their use. These compositions encompass interleukin-4 (IL-4) muteins. The disclosed methods encompass administering an IL-4 to treat neoplastic diseases, autoimmune diseases, infectious diseases or for expanding a hematopoietic cell population.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: August 11, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: K. Christopher Garcia, Darren L. Bates, Ignacio Moraga
  • Patent number: 10736974
    Abstract: Carbamate and beta-amino acid urea-based scaffolds that have high binding affinity to PSMA are disclosed. These scaffolds can be radiolabeled and used for imaging cells and tumors that express PSMA or for cancer radiotherapy. These compounds also can comprise a fluorescent dye and be used for imaging cells and tumors that express PSMA or for photodynamic therapy.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: August 11, 2020
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Martin G. Pomper, Ronnie C. Mease, Sangeeta Ray, Ying Chen, Xing Yang
  • Patent number: 10739262
    Abstract: A quantitative method for diagnosing an autoimmune disease or an infectious disease comprising performing an automated diagnostic assay, comprising: incubating a capture reagent with a streptavidin-coated medium to form a solid phase complex, wherein the capture reagent is a biotinylated autoantigen or infectious disease antigen; washing the solid phase complex to remove excess capture reagent; incubating the solid phase complex with a serum sample to form an immune complex; washing the immune complex to remove any unbound sample; incubating the immune complex with a conjugate to create an immune-conjugate complex; washing the immune-conjugate complex to remove any unbound conjugate; introducing a substrate capable of generating a quantifiable response; and calibrating the response generated from introducing the substrate.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: August 11, 2020
    Assignee: HYCOR Biomedical, LLC
    Inventors: Mark David Van Cleve, Elaine Grace Taine, Douglas John Canfield, Stephanie TuVi Ortega, Taylor Addison Reid
  • Patent number: 10729675
    Abstract: A gossypol isatin Schiff base compound with antitumor activities represented by formula I: R1 and R2 are independently hydrogen, alkyl, cycloalkyl, alkoxy, nitro, halogen, unsubstituted or substituted phenyl, or unsubstituted or substituted benzyl. A method of preparing the compound of formula I is also disclosed.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: August 4, 2020
    Assignee: SHAANXI UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Chengyuan Liang, Xingke Ju, Shunjun Ding, Lei Tian, Yuzhi Liu, Xiaolin Xie, Dezhu Zhang, Wenbo Yao, Dan Yang